Eunice Wandia Mailu
Text For Abstract
Many resource-poor countries have a large and expanding private health sector and there is growing evidence that increasing numbers of patients with tuberculosis (TB) seek care from private-for-profit providers. In recent years the World Health Organization (WHO) has begun to address the issue of private-for-profit providers in TB prevention and care through an evolving global strategy called Public-Private Mix (PPM). PPM for TB care and control is defined as the involvement of all health care providers in TB control so as to promote the use of International Standards for TB Care in all health sectors and thereby achieve national and global TB control targets (World Health Organization, 2012). In 2014, the WHO launched the End TB strategy with an ambitious goal of ending the global TB epidemic by 2035. One of the components of the Second Pillar of the End TB Strategy fully embraces PPM and emphasizes the importance of engaging communities, Civil Society Organizations (CSOs) and all public and private care providers (World Health Organization, 2014).
The aim of this study is to assess, at the national level, TB control activities in the private-for-profit health sector in Kenya between 2013 and 2017 and compare the findings with what has been reported in the public health sector (including government, FBO and NGO sectors).Specific objectives The completeness of data collection for selected key variables Numbers of notified TB cases per year by socio-demographic and clinical characteristics including type and category TB-HIV collaborative activities, including HIV testing uptake, and use of ART and CPT for those found to be co-infected Treatment outcomes of all notified TB cases and in relation to HIV status.
What is this research about?
Young children admitted to hospital with signs of infection are treated with antibiotics. However, bacteria are increasingly becoming resistant to the antibiotics that are normally used. This may make it harder to recover from their illnesses. In Africa, alternative drugs that work are expensive and may themselves cause the bacteria to become resistant. New alternatives are therefore needed. One drug that might be able to be used as an alternative is Fosfomycin. This drug is used in Europe and America to treat some infections in adults and children. The drug can now be obtained cheaply since it has come off patent. Since it has not been used a lot in this part of the world the risk of bacterial resistance is likely to be low. However, more information about the drug is needed to inform the best dose to use in newborns.